Role of antiretroviral regimes in HIV‐1 patients in reducing immune activation

Antonio J. Jiménez, Rosa García(Universidad Autónoma de Madrid), Laura Molero, Manuel Fedz‐Guerrero(Hospital Universitario Fundación Jiménez Díaz), Ana Belén Jiménez(Junta de Castilla y León), Dolores Subirá(Hospital Universitario de Guadalajara), Miguel Górgolas(Hospital Universitario Fundación Jiménez Díaz), Susana Castañón(Hospital Universitario Fundación Jiménez Díaz)
Immunology
May 1, 2002
10.1046/j.1365-2567.2002.01399.x
Cited by 5

Related Papers

Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain
|PLoS ONE|2018|179
Severe Dengue Virus Infection in Travelers: Risk Factors and Laboratory Indicators
|The Journal of Infectious Diseases|2007|173
Hospital-Acquired Infectious Endocarditis Not Associated with Cardiac Surgery: An Emerging Problem
|Clinical Infectious Diseases|1995|170
The Spectrum of Cardiovascular Infections due to Salmonella enterica
|Medicine|2004|155
Initial Use of Echinocandins Does Not Negatively Influence Outcome in Candida parapsilosis Bloodstream Infection: A Propensity Score Analysis
|Clinical Infectious Diseases|2014|124